Lanzl, Ines http://orcid.org/0000-0003-2850-8976
Deuter, Christoph M E
Lorenz, Katrin http://orcid.org/0000-0002-1755-7396
Geerling, Gerd http://orcid.org/0000-0003-2034-3687
,
Funding for this research was provided by:
Technische Universität München
Article History
Received: 7 June 2023
Revised: 2 January 2024
Accepted: 11 February 2024
First Online: 9 May 2024
Declarations
:
: Members of the PERSPECTIVE German study group were the following: Christophe Deuter (Augenklinik des Universitätsklinikums Tübingen, Tübingen), Katrin Engelmann (Klinikum Chemnitz gGmbH, Chemnitz), Nicole Eter (Universitaets-Augenklinik Muenster, Muenster), Gerd Geerling (Augenklinik des Universitätsklinikums Düsseldorf, Düsseldorf), Andrea Hoeck (Universitäts-Augenklinik Bonn, Bonn), Kai Januschowski (Mount Saint Peter Eye Clinic, Trier; University of Tübingen, Tübingen), Daniel Kampik (Department of Ophthalmology, University Hospitals Würzburg, Würzburg), Karsten Klabe (Internationale Innovative Ophthalmochirurgie, Düsseldorf), Thomas Kohnen (Klinikum der Johann Wolfgang Goethe-Universitaet Frankfurt, Frankfurt), Lothar Krause (Städtisches Klinikum Dessau, Dessau-Rosslau), Friedrich E Kruse (Augenklinik des Universitetsklinikums Erlangen, Erlangen), Ines Lanzl (Chiemsee Augen Tagesklinik, Prien), Katrin Lorenz (Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz), Elisabeth M. Messmer (Department of Ophthalmology, Ludwig Maximilians University, Munich), Arthur Mueller (Klinik für Augenheilkunde Universitätsklinikum Augsburg, Augsburg), Thomas Neuhann (MVZ Professor Neuhann, GmbH, Munich), Berthold Seitz (Universitaetsklinikum des Saarlandes, Homburg), Martin Spitzer (Universitätsklinikums Hamburg-Eppendorf, Hamburg), Hagen Thieme (Otto-von-Guericke-Universität, Medizinische Fakultät, Universitätsklinikum Magdeburg A.ö.R., Magdeburg), Christian van Oterendorp (University Medical Center Göttingen, Department of Ophthalmology, Göttingen), Manfred Zierhut (Augenklinik des Universitätsklinikums Tübingen, Tübingen). For the full list of investigators, please refer to the primary study article [].
: The PERSPECTIVE study was a 12-month, European, prospective, non-interventional, multicenter, observational cohort study. In line with the European Medicines Agency (EMA) requirements, the study was registered under the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP<sup>®</sup>) European Union electronic Register of Post-Authorisation Studies (EU PAS Register) (EU PAS Register Number: EUPAS22376). All procedures performed in this study were in accordance with the ethical standards of the participating institutions and with the principles of the World Medical Association (WMA) Declaration of Helsinki of 1964 as revised in 2013. The protocol was centrally approved by the Institutional Review Board or Independent Ethics Committee at the University of Würzburg ahead of study initiation (reference: 304/16-mk). All other centers/institutions followed this approval and are listed alongside the relevant investigator in the PERSPECTIVE Germany study group section above. This study did not involve animal research.
: Informed consent was obtained from all individual participants included in the study prior to their enrollment.
: Ines Lanzl has received speaker fees from Allergan, Bayer, Novartis, Santen, Shire, and Théa Pharma. Christoph Deuter has received speaker fees from AbbVie, Amgen, Novartis, Santen, Théa Pharma, and honoraria for consulting from Alimera and Santen. Katrin Lorenz has received a research grant from Santen. Gerd Geerling has received a research grant and honoraria for consulting and presenting study results on behalf of Santen, as well as Allergan, Bausch & Lomb, Dompé Farmaceutici, Holostem, Leica Microsystems, Med1Ventures, Novartis, Oculus, Sun Pharma, Tearlab, Tear Science, Théa Pharma, and Visufarma.